Home » Market News » DirectorsTalk Highlights » Evgen Pharma poised for a pivotal year
Evgen Pharma Plc

Evgen Pharma poised for a pivotal year

2018 is a key year in the development of Evgen Pharma Plc (LON:EVG), the Cheshire-based business which has made rapid progress since joining AIM.

It now has two Phase II clinical trials underway, one in advanced breast cancer and one in a type of stroke known as a subarachnoid haemorrhage (SAH).

Evgen was founded in 2007 to have a lower risk profile than many in its peer group. Its drug pipeline is based on sulforaphane, a naturally occurring molecule originating in brassicas such as broccoli. A huge amount of academic research has been published on sulforaphane, highlighting its potential in medical conditions ranging from solid tumour cancers through multiple sclerosis, Parkinson’s disease and autism.

 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.